目的 通过卫生技术评估新型唑烷酮类抗菌药康替唑胺，为医院遴选、临床合理使用新型噁唑烷酮药物提供循证依据。方法 按照药品目录遴选评价管理指南评估细则对国产康替唑胺片进行量化评估，通过检索中国知网、万方、维普、PubMed、Metstr等中外文数据库及相关政府网站获得康替唑胺的适应证、药理作用、指南推荐情况、药品价格等信息，按照药学特性、有效性、安全性、经济性及其他属性量化评价，汇总得分并根据评分划分推荐级别。结果 综合评估结果显示，康替唑胺药学特性18.8分，有效性15分，安全性14.2分，经济性14分，其他属性10分，总得分72分，可推荐进入医疗机构用药目录。结论 康替唑胺作为新品种可以推荐进入医疗机构用药目录，对于临床上利奈唑胺无法治愈的耐甲氧西林金黄色葡萄球菌（MRSA）感染，康替唑胺片有望成为更加安全的抗菌药物选择。

Objective To provide evidence-based basis for hospital selection and clinical rational use of new oxazolidone drugs, new antiseptic drug contezolamide was evaluated by health technology. Methods Quantitative evaluation of domestic Contezolid Tablets was carried out according to the evaluation rules of drug catalog selection and evaluation management guidelines. Information of indications, pharmacological effects, guidelines recommendation, drug price, and other information of contezolid were obtained by searching CNKI, Wanfang, VIP, PubMed, Metstr, and other Chinese and foreign databases as well as relevant government websites. According to the quantitative evaluation of pharmaceutical characteristics, efficacy, safety, economy and other attributes, the scores were summarized and the recommendation levels were divided according to the scores. Results The comprehensive evaluation results showed that contezolamide scored 18.8 points for pharmaceutical characteristics, 15 points for effectiveness, 14.2 points for safety, 14 points for economy and 10 points for other attributes, with a total score of 72 points, which can be recommended to be included in the drug list of medical institutions. Conclusion As a new product, contezolid can be recommended to enter the drug catalog of medical institutions. For the methicillin-resistant Staphylococcus aureus (MRSA) infection that cannot be cured by linezolid clinically, Contezolid Tablets are expected to become a safer antibacterial drug choice.

R978.1